Ludovinin et al. showed that 6 patients with PIK3CA mutation had a shorter time to tumor progression (TTP) after EGFR TKI treatment, but the EGFR TKI treatment response was not associated to PIK3CA mutation (p = 0.61)7. The gene discussed is PIK3CA; the disease is neoplasm.